Quantcast

Latest Bacillus Calmette-Guérin Stories

2008-10-20 09:00:42

Dutch biopharma company Crucell and the Aeras Global TB Vaccine Foundation have started a Phase I clinical trial in Kenya of the jointly developed tuberculosis vaccine candidate, AERAS-402/Crucell Ad35. This study of the new tuberculosis (TB) vaccine candidate in Kenya will be conducted by the Walter Reed Project-Kenya (WRP) at Kombewa, near Kisumu, western Kenya. The main parameters of the study will be to test the safety of the candidate in healthy adults, all of whom have been...

2008-09-06 03:00:05

By Anonymous Professor Brigitte Gicquel is head of the Mycobacterial Genetics unit at the Pasteur Institute in Paris, France. After completing her undergraduate and doctoral studies at the University of Paris VII, she joined the Pasteur Institute in 1973 and has spent much of her scientific career concentrating on the genetics of Mycobacterium tuberculosis. Gicquel coordinated both the European Commission's efforts to find a vaccine more efficient than bacille Calmette- Guerin (BCG) for...

2008-08-28 06:01:10

MELBOURNE, Australia, Aug. 28 /PRNewswire/ -- Students attending US colleges that require tuberculosis (TB) testing will now benefit from interferon-gamma release assays (IGRA) such as QuantiFERON(R)-TB Gold (QFT(TM)), with the release of update TB testing guidelines from the American College Health Association (ACHA). In the past, students would have been tested with the tuberculin skin test (TST) which is known to suffer from false-positive results due to cross-reactivity with BCG vaccine...

2008-08-26 09:01:20

SEATTLE, Aug. 26 /PRNewswire/ -- IDRI announced today it has been awarded a $6.3 million grant from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), for the development of adjuvant combinations specifically designed to enhance the immune response to new tuberculosis vaccine antigens. This four-year grant will enable the selection of the most promising adjuvant formulations, their evaluation in preclinical models and the...

2008-08-18 09:01:01

BELLEVILLE, ON, Aug. 18 /PRNewswire-FirstCall/ -- Bioniche Life Sciences Inc. (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced that its first Phase III clinical trial with a formulation of Mycobacterial Cell Wall-DNA Complex (MCC), trademarked Urocidin, for the treatment of bladder cancer, is progressing well. The Data Safety Monitoring Committee held its fifth scheduled meeting regarding this clinical trial on August 14, 2008. The role of...

2008-07-23 12:01:24

The University of Oxford and Emergent BioSolutions have formed a joint venture, The Oxford-Emergent Tuberculosis Consortium, to further develop MVA85A, a clinically advanced vaccine candidate for the prevention of tuberculosis. The University of Oxford, through its technology transfer office, Isis Innovation, has exclusively licensed the MVA85A tuberculosis (TB) vaccine candidate and related technology to the consortium. The consortium will work with the Aeras Global TB Vaccine Foundation...

2008-07-23 00:00:46

The University of Oxford and Emergent BioSolutions Inc. (NYSE:EBS) announced today that they have formed a joint venture, The Oxford-Emergent Tuberculosis Consortium Ltd. (the "Consortium"), to further develop MVA85A, the world's most clinically advanced vaccine candidate for the prevention of tuberculosis. The University of Oxford, through its technology transfer office, Isis Innovation Limited, has exclusively licensed the MVA85A tuberculosis vaccine candidate and related technology to the...

2008-03-14 04:05:00

CHAPEL HILL "“ A new tuberculosis vaccine successfully tested at the University of North Carolina at Chapel Hill is easier to administer and store and just as effective as one commonly used worldwide. Scientists at the UNC School of Pharmacy led by Tony Hickey, Ph.D., vetted a dry powder vaccine provided by Harvard University that is administered using an inhaler. The results of the vaccine test are being published this week in the Proceedings of the National Academy of Sciences. "It is...

2007-11-09 06:00:14

By Veeser, Peggy Ingram Smith, Phillip Karl; Handy, Barry; Martin, Sharon R Abstract. Detecting and managing Mycobacterium tuberculosis (TB) infection in a health-science center population is a clinical dilemma. Tuberculin skin tests are still the preferred method for detecting present or past infection of TB. The authors discuss the performance of whole blood interferon gamma release assay test commercially known as QuantiFERON-TB Gold Test (QFT-G) as an additional tool for a TB...

2006-04-06 18:11:09

LONDON (Reuters) - The BCG vaccine against childhood tuberculosis is cost-effective and should be used in countries with a high incidence of the disease, researchers said on Friday. There has been debate in the medical and scientific community about the widespread use of BCG and its role in countries which do not have high infection rates. But an analysis of the impact and cost of the vaccine in different regions of the world showed it is particularly effectively in southeast Asia,...


Latest Bacillus Calmette-Guérin Reference Libraries

45_255d6ba67dfe6f32b9c7c31f338bf912
2011-04-18 22:11:24

Mycobacterium bovis is a slow-growing, aerobic bacterium and the causative agent of tuberculosis in cattle. Similar to M. tuberculosis, M. bovis can jump the species barrier and cause tuberculosis in humans. It is estimated that M. bovis was responsible for more losses among farm animals than all other diseases combined in the first half of the 20th century. Infection happens after bacterium is ingested. It is generally transmitted to humans via infected milk. Actual human infections are...

More Articles (1 articles) »
Word of the Day
bibliopole
  • A bookseller; now, especially, a dealer in rare and curious books.
This word comes from a Greek phrase meaning 'book seller.'
Related